Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aditxt, Inc.

< Previous 1 2 3 Next >
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $20.0 Million Public Offering
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt to Participate in the 2022 Virtual Growth Conference
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Signs Non-Binding Letter of Intent to Acquire Point-of-Care Diagnostic Technology Development Company
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Proposed Public Offering of Common Stock and Warrants
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Webinar at 2pm ET to Explore PRESECO Results
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $4.25 Million Public Offering
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Pricing of $4.25 Million Public Offering
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company with Anti-Viral COVID-19 Therapy
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
From Aditxt, Inc.
Via Business Wire
Tickers ADTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.